Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

XELOX III. Capecitabine (Xeloda) in Combination With Oxaliplatin (Eloxatin) as First-line Treatment of Patients With Advanced or Metastatic Colorectal Cancer. A Randomized Phase II Study

NCT00212615 is registered in ClinicalTrials.gov with Odense University Hospital as lead sponsor.

NCT NCT00212615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00212615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
XELOX III. Capecitabine (Xeloda) in Combination With Oxaliplatin (Eloxatin) as First-line Treatment of Patients With Advanced or Metastatic Colorectal Cancer. A Randomized Phase II Study
Lead sponsor
Odense University Hospital
Phase
Phase 2/3
Overall status
Completed
Start date
February 29, 2004
Completion date
October 31, 2008
Enrollment
116 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

c04.588.274.476.411.307